These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 6352639)
1. Ceftazidime - a significant advance in the treatment of cystic fibrosis. David TJ; Phillips BM; Connor PJ J Antimicrob Chemother; 1983 Jul; 12 Suppl A():337-40. PubMed ID: 6352639 [TBL] [Abstract][Full Text] [Related]
2. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636 [TBL] [Abstract][Full Text] [Related]
3. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. Gold R; Jin E; Levison H; Isles A; Fleming PC J Antimicrob Chemother; 1983 Jul; 12 Suppl A():331-6. PubMed ID: 6352638 [TBL] [Abstract][Full Text] [Related]
4. Experience with ceftazidime in cystic fibrosis. Dodge J; Zamiri I; Goodchild M; Ingram P J Antimicrob Chemother; 1983 Jul; 12 Suppl A():325-9. PubMed ID: 6352637 [TBL] [Abstract][Full Text] [Related]
5. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. Strandvik B; Malmborg AS; Alfredson H; Ericsson A J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633 [TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin. Heilesen AM; Permin H; Koch C; Høiby N Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770 [TBL] [Abstract][Full Text] [Related]
14. High dosage tobramycin treatment of children with cystic fibrosis. Bacteriological effect and clinical ototoxicity. Thomsen J; Friis B Int J Pediatr Otorhinolaryngol; 1979 Jul; 1(1):33-40. PubMed ID: 553884 [TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. Byrne S; Maddison J; Connor P; Doughty I; Dodd M; Jenney M; Webb AK; David TJ J Antimicrob Chemother; 1995 Jul; 36 Suppl A():135-43. PubMed ID: 8543489 [TBL] [Abstract][Full Text] [Related]
17. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Gold R; Overmeyer A; Knie B; Fleming PC; Levison H Pediatr Infect Dis; 1985; 4(2):172-7. PubMed ID: 3885181 [TBL] [Abstract][Full Text] [Related]
18. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia. Chin NX; Neu HC Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis]. Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880 [TBL] [Abstract][Full Text] [Related]
20. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis. Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061 [No Abstract] [Full Text] [Related] [Next] [New Search]